Clinical and Molecular Hepatology (대한간학회지)

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

  • The Korean Association for the Study of the Liver, The Korean Association for the Study of the Liver (The Korean Association for the Study of the Liver (KASL))
  • Received : 2013.10.30
  • Accepted : 2013.11.07
  • Published : 2013.12.25
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344-353. https://doi.org/10.1002/hep.24376
  2. Loria P, Adinolfi LE, Bellentani S, Bugianesi E, Grieco A, Fargion S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010;42:272-282. https://doi.org/10.1016/j.dld.2010.01.021
  3. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023. https://doi.org/10.1002/hep.25762
  4. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-728. https://doi.org/10.7326/0003-4819-143-10-200511150-00009
  5. Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 2005;41:64-71. https://doi.org/10.1002/hep.20543
  6. Whalley S, Puvanachandra P, Desai A, Kennedy H. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin Med 2007;7:119-124. https://doi.org/10.7861/clinmedicine.7-2-119
  7. Lee JW, Cho YK, Ryan M, Kim H, Lee SW, Chang E, et al. Serum uric Acid as a predictor for the development of nonalcoholic Fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut Liver 2010;4:378-383. https://doi.org/10.5009/gnl.2010.4.3.378
  8. Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007;47:239-244. https://doi.org/10.1016/j.jhep.2007.02.007
  9. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124-131. https://doi.org/10.1053/j.gastro.2010.09.038
  10. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010;51:1979-1987. https://doi.org/10.1002/hep.23593
  11. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57:1357-1365. https://doi.org/10.1002/hep.26156
  12. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21:138-143. https://doi.org/10.1111/j.1440-1746.2005.04086.x
  13. Bae JC, Cho YK, Lee WY, Seo HI, Rhee EJ, Park SE, et al. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol 2010;105:2389-2395. https://doi.org/10.1038/ajg.2010.275
  14. Choi SY, Kim D, Kim HJ, Kang JH, Chung SJ, Park MJ, et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am J Gastroenterol 2009;104:1953- 1960. https://doi.org/10.1038/ajg.2009.238
  15. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006;45:600-606. https://doi.org/10.1016/j.jhep.2006.06.013
  16. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009;29:113-119. https://doi.org/10.1111/j.1478-3231.2008.01718.x
  17. Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in korean men: 5-year prospective cohort study. Hepatology 2013;57:1378-1383. https://doi.org/10.1002/hep.26183
  18. Chung GE, Kim D, Kim W, Yim JY, Park MJ, Kim YJ, et al. Nonalcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol 2012;57:150-156. https://doi.org/10.1016/j.jhep.2012.02.027
  19. Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011;33:801-814. https://doi.org/10.1111/j.1365-2036.2011.04579.x
  20. Cerda C, Perez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir- Petermann T, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007;47:412-417. https://doi.org/10.1016/j.jhep.2007.04.012
  21. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-285. https://doi.org/10.1111/j.1365-2036.2011.04724.x
  22. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404
  23. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet 2005;366:1059-1062. https://doi.org/10.1016/S0140-6736(05)67402-8
  24. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43:617-649. https://doi.org/10.3109/07853890.2010.518623
  25. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454-462. https://doi.org/10.1002/hep.23312
  26. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010;59:969-974. https://doi.org/10.1136/gut.2009.205088
  27. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-1978. https://doi.org/10.1002/hep.23527
  28. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121. https://doi.org/10.1053/j.gastro.2005.04.014
  29. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, Mc- Cullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419. https://doi.org/10.1016/S0016-5085(99)70506-8
  30. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004;53:750-755. https://doi.org/10.1136/gut.2003.019984
  31. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-873. https://doi.org/10.1002/hep.21327
  32. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008;103:2263- 2271. https://doi.org/10.1111/j.1572-0241.2008.02034.x
  33. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7:234-238. https://doi.org/10.1016/j.cgh.2008.11.005
  34. Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009;44:1236-1243. https://doi.org/10.1080/00365520903171284
  35. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51:595-602. https://doi.org/10.1002/hep.23314
  36. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714-1719. https://doi.org/10.1002/hep.1840220616
  37. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-138.
  38. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007;11:1-16, vii. https://doi.org/10.1016/j.cld.2007.02.009
  39. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004;40:578-584. https://doi.org/10.1016/j.jhep.2004.02.013
  40. Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004;99:292-298. https://doi.org/10.1111/j.1572-0241.2004.04059.x
  41. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006;43:682-689. https://doi.org/10.1002/hep.21103
  42. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009;24:248-254. https://doi.org/10.1111/j.1440-1746.2008.05640.x
  43. Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003;38:420-427.
  44. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006;29:1325-1330. https://doi.org/10.2337/dc06-0135
  45. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30:1212-1218. https://doi.org/10.2337/dc06-2247
  46. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I, et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010;53:713-718. https://doi.org/10.1016/j.jhep.2010.04.030
  47. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005;112:2130-2137. https://doi.org/10.1161/CIRCULATIONAHA.105.552547
  48. Lee DH, Silventoinen K, Hu G, Jacobs DR, Jr., Jousilahti P, Sundvall J, et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J 2006;27:2170-2176. https://doi.org/10.1093/eurheartj/ehl086
  49. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007;191:391-396. https://doi.org/10.1016/j.atherosclerosis.2006.04.006
  50. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007;27:127-133. https://doi.org/10.1161/01.ATV.0000251993.20372.40
  51. Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis 2009;203:581-586. https://doi.org/10.1016/j.atherosclerosis.2008.07.024
  52. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med 2008;25:476-481. https://doi.org/10.1111/j.1464-5491.2008.02410.x
  53. Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010;25:352-356. https://doi.org/10.1111/j.1440-1746.2009.05998.x
  54. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-384. https://doi.org/10.1016/j.jhep.2010.04.008
  55. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-2961. https://doi.org/10.1111/j.1572-0241.2001.04667.x
  56. Brouwers MC, van Greevenbroek MM, Cantor RM. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009;137:1536. https://doi.org/10.1053/j.gastro.2009.03.065
  57. Tarnoki AD, Tarnoki DL, Bata P, Littvay L, Osztovits J, Jermendy G, et al. Heritability of non-alcoholic fatty liver disease and association with abnormal vascular parameters: a twin study. Liver Int 2012;32:1287-1293. https://doi.org/10.1111/j.1478-3231.2012.02823.x
  58. Kim CW, Chang Y, Sung E, Shin H, Ryu S. Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men. Metabolism 2012;61:1182-1188. https://doi.org/10.1016/j.metabol.2012.01.007
  59. Lee YJ, Lee HR, Lee JH, Shin YH, Shim JY. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab Med 2010;48:175-180.
  60. Ryoo JH, Choi JM, Moon SY, Suh YJ, Shin JY, Shin HC, et al. The clinical availability of non alcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men: 5-year's prospective cohort study. Atherosclerosis 2013;227:398-403. https://doi.org/10.1016/j.atherosclerosis.2013.01.002
  61. Choi JH, Rhee EJ, Bae JC, Park SE, Park CY, Cho YK, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res 2013;44:115-120. https://doi.org/10.1016/j.arcmed.2013.01.007
  62. Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012;56:605-613. https://doi.org/10.1002/hep.25593
  63. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009;49:1017-1044. https://doi.org/10.1002/hep.22742
  64. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004;50:1344-1355. https://doi.org/10.1373/clinchem.2004.032227
  65. Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 2002;8:1114-1122. https://doi.org/10.1053/jlts.2002.36740
  66. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007;189:W320-W323. https://doi.org/10.2214/AJR.07.2123
  67. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-750. https://doi.org/10.1053/gast.2002.35354
  68. Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006;239:105-112. https://doi.org/10.1148/radiol.2391050361
  69. Fishbein M, Castro F, Cheruku S, Jain S, Webb B, Gleason T, et al. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 2005;39:619-625. https://doi.org/10.1097/00004836-200508000-00012
  70. Thomas EL, Hamilton G, Patel N, O'Dwyer R, Dore CJ, Goldin RD, et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005;54:122-127. https://doi.org/10.1136/gut.2003.036566
  71. Kim KM, Choi WB, Park SH, Yu E, Lee SG, Lim YS, et al. Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. J Gastroenterol 2007;42:382-388. https://doi.org/10.1007/s00535-007-2016-1
  72. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010;36:1825-1835. https://doi.org/10.1016/j.ultrasmedbio.2010.07.005
  73. de Ledinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Noninvasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012;32:911-918. https://doi.org/10.1111/j.1478-3231.2012.02820.x
  74. Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012;32:902-910. https://doi.org/10.1111/j.1478-3231.2012.02781.x
  75. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011;259:749-756. https://doi.org/10.1148/radiol.11101942
  76. Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology 2013;268:411-419. https://doi.org/10.1148/radiol.13121193
  77. Ipekci SH, Basaranoglu M, Sonsuz A. The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2003;36:371. https://doi.org/10.1097/00004836-200304000-00021
  78. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286- 1292. https://doi.org/10.1053/jhep.2003.50229
  79. Suzuki A, Lymp J, Sauver JS, Angulo P, Lindor K. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int 2006;26:1209-1216. https://doi.org/10.1111/j.1478-3231.2006.01362.x
  80. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-854. https://doi.org/10.1002/hep.21496
  81. Qureshi K, Clements RH, Abrams GA. The utility of the "NAFLD fibrosis score" in morbidly obese subjects with NAFLD. Obes Surg 2008;18:264-270. https://doi.org/10.1007/s11695-007-9295-8
  82. Wong VW, Wong GL, Chim AM, Tse AM, Tsang SW, Hui AY, et al. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol 2008;103:1682-1688.
  83. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47:455-460.
  84. Guturu P, Steffer K, Petersen JR, Snyder N. A new risk index for the estimation of fibrosis in non alcoholic fatty liver disease (NAFLD): comparison with the Mayo Score and the AST platelet ratio index (APRI) [Abstract]. Hepatology 2008;48(Suppl 1):522A.
  85. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-1447. https://doi.org/10.1136/gut.2007.146019
  86. Cales P, Laine F, Boursier J, Deugnier Y, Moal V, Oberti F, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009;50:165-173.
  87. Ruffillo GE, Fassio E, Alvarez E, Landeira G, Longo CG, Domínguez N, et al. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease [Abstract]. Hepatology 2009;50(Suppl 4):782A.
  88. Parker R CP, McCune A. Can clinical scoring systems replace liver biopsy in non-alcoholic fatty liver disease? [Abstract]. J Hepatol 2009;51;189.
  89. Fuji H EM, Fukushima W, Tamori A, Sakaguchi H, Kawada N. Application of non-invasive laboratory tests for the assessment of fi brosis staging in Japanese patients with NAFLD. [Abstract]. J Hepatol 2009;51;134.
  90. Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011;46:257-268. https://doi.org/10.1007/s00535-010-0305-6
  91. Pimentel SK, Strobel R, Goncalves CG, Sakamoto DG, Ivano FH, Coelho JC. Evaluation of the nonalcoholic fat liver disease fibrosis score for patients undergoing bariatric surgery. Arq Gastroenterol 2010;47:170-173. https://doi.org/10.1590/S0004-28032010000200010
  92. Yu SJ, Kim DH, Lee JH, Chung GE, Yim JY, Park MJ, et al. Validation of P2/MS and other noninvasive fibrosis scoring systems in the Korean population with nonalcoholic fatty liver disease. Korean J Gastroenterol 2011;57:19-27. https://doi.org/10.4166/kjg.2011.57.1.19
  93. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007;46:582-589. https://doi.org/10.1002/hep.21768
  94. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44:27-33.
  95. Adams LA, Angulo P. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis 2007;11:25-35, viii. https://doi.org/10.1016/j.cld.2007.02.004
  96. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40:820-826.
  97. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989;111:473-478. https://doi.org/10.7326/0003-4819-111-6-473
  98. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-1362. https://doi.org/10.1002/hep.510300604
  99. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100. https://doi.org/10.1053/gast.2001.25540
  100. Park HS, Kim MW, Shin ES. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci 1995;10:414-421. https://doi.org/10.3346/jkms.1995.10.6.414
  101. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-419. https://doi.org/10.1136/gut.2003.027581
  102. Suzuki A, Lindor K, St Saver J, Lymp J, Mendes F, Muto A, et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005;43:1060-1066. https://doi.org/10.1016/j.jhep.2005.06.008
  103. Kantartzis K, Thamer C, Peter A, Machann J, Schick F, Schraml C, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 2009;58:1281-1288. https://doi.org/10.1136/gut.2008.151977
  104. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009;136:1552-1560. https://doi.org/10.1053/j.gastro.2009.01.048
  105. Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010;33:2156-2163. https://doi.org/10.2337/dc10-0856
  106. Jin YJ, Kim KM, Hwang S, Lee SG, Ha TY, Song GW, et al. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors. J Gastroenterol Hepatol 2012;27:1341-1347. https://doi.org/10.1111/j.1440-1746.2012.07165.x
  107. Schafer S, Kantartzis K, Machann J, Venter C, Niess A, Schick F, et al. Lifestyle intervention in individuals with normal versus impaired glucose tolerance. Eur J Clin Invest 2007;37:535-543. https://doi.org/10.1111/j.1365-2362.2007.01820.x
  108. Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009;50:1105-1112. https://doi.org/10.1002/hep.23129
  109. Bonekamp S, Barone BB, Clark J, Stewart KJ. The effects of an exercise training intervention on hepatic steatosis [Abstract]. Hepatology 2008;48(Suppl 1):806A.
  110. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004;20:623-628. https://doi.org/10.1111/j.1365-2036.2004.02153.x
  111. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-129. https://doi.org/10.1002/hep.23276
  112. Wang CL, Liang L, Fu JF, Zou CC, Hong F, Xue JZ, et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol 2008;14:1598-1602. https://doi.org/10.3748/wjg.14.1598
  113. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;57:157-166. https://doi.org/10.1016/j.jhep.2012.02.023
  114. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005;100:1072-1081. https://doi.org/10.1111/j.1572-0241.2005.41334.x
  115. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224-229. https://doi.org/10.1016/0168-8278(91)90942-5
  116. World Gastroenterology Organisation (WGO). Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. WGO web site, . Accessed 2013.
  117. Kang H, Greenson JK, Omo JT, Chao C, Peterman D, Anderson L, et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 2006;101:2247-2253. https://doi.org/10.1111/j.1572-0241.2006.00719.x
  118. Toshimitsu K, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa Y, et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 2007;23:46-52. https://doi.org/10.1016/j.nut.2006.09.004
  119. Browning JD, Baker JA, Rogers T, Davis J, Satapati S, Burgess SC. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 2011;93:1048-1052. https://doi.org/10.3945/ajcn.110.007674
  120. National Institute of Food and Drug Safety Evaluation (NIFDS). Influence of dietary intake on non-alcoholic fatty liver disease in Korean. NIFDS web site, . Accessed 2013.
  121. Haufe S, Engeli S, Kast P, Bohnke J, Utz W, Haas V, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 2011;53:1504-1514. https://doi.org/10.1002/hep.24242
  122. Korea Centers for Disease Control and Prevention (KCDC). Korea Health Statistics 2009: Korea National Health and Nutrition Examination Survey.KCDC web site, < http://knhanes.cdc.go.kr/knhanes/ index.do >. Accessed 2013.
  123. Shojaee-Moradie F, Baynes KC, Pentecost C, Bell JD, Thomas EL, Jackson NC, et al. Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism. Diabetologia 2007;50:404-413. https://doi.org/10.1007/s00125-006-0498-7
  124. van der Heijden GJ, Wang ZJ, Chu ZD, Sauer PJ, Haymond MW, Rodriguez LM, et al. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents. Obesity (Silver Spring) 2010;18:384-390. https://doi.org/10.1038/oby.2009.274
  125. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:639-644. https://doi.org/10.1016/j.cgh.2006.02.004
  126. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009;49:80-86. https://doi.org/10.1002/hep.22575
  127. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alphatocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001;15:1667-1672. https://doi.org/10.1046/j.1365-2036.2001.01083.x
  128. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-2490. https://doi.org/10.1111/j.1572-0241.2003.08699.x
  129. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004;2:1107-1115. https://doi.org/10.1016/S1542-3565(04)00457-4
  130. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-1090. https://doi.org/10.1111/j.1572-0241.2005.41583.x
  131. Yakaryilmaz F, Guliter S, Savas B, Erdem O, Ersoy R, Erden E, et al. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern Med J 2007;37:229-235. https://doi.org/10.1111/j.1445-5994.2006.01295.x
  132. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006;4:1537-1543. https://doi.org/10.1016/j.cgh.2006.09.025
  133. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104.
  134. Bjelakovic G, Gluud L, Nikolova D, Bjelakovic M, Nagorni A, Gluud C. Meta-analysis: antioxidant supplements for liver diseases-the Cochrane Hepato-Biliary Group. Aliment Pharmacol Ther 2010;32:356-367. https://doi.org/10.1111/j.1365-2036.2010.04371.x
  135. Miller ER, 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46. https://doi.org/10.7326/0003-4819-142-1-200501040-00110
  136. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685. https://doi.org/10.1056/NEJMoa0907929
  137. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-1668. https://doi.org/10.1001/jama.2011.520
  138. Gerss J, Kopcke W. The questionable association of vitamin E supplementation and mortality--inconsistent results of different meta-analytic approaches. Cell Mol Biol (Noisy-le-grand) 2009;55(Suppl):OL1111- OL1120.
  139. Dietrich M, Jacques PF, Pencina MJ, Lanier K, Keyes MJ, Kaur G, et al. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role? Atherosclerosis 2009;205:549-553. https://doi.org/10.1016/j.atherosclerosis.2008.12.019
  140. Berry D, Wathen JK, Newell M. Bayesian model averaging in metaanalysis: vitamin E supplementation and mortality. Clinical Trials 2009;6:28-41. https://doi.org/10.1177/1740774508101279
  141. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer : the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549-1556. https://doi.org/10.1001/jama.2011.1437
  142. Khoshbaten M, Aliasgarzadeh A, Masnadi K, Tarzamani MK, Farhang S, Babaei H, et al. N-acetylcysteine improves liver function in patients with non-alcoholic Fatty liver disease. Hepat Mon 2010;10:12-16.
  143. Abdelmalek MF, Sanderson SO, Angulo P, Soldevila-Pico C, Liu C, Peter J, et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009;50:1818-1826. https://doi.org/10.1002/hep.23239
  144. Merat S, Aduli M, Kazemi R, Sotoudeh M, Sedighi N, Sohrabi M, et al. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig Dis Sci 2008;53:2246-2250. https://doi.org/10.1007/s10620-007-0109-6
  145. Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L, et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2009;30:999-1009. https://doi.org/10.1111/j.1365-2036.2009.04122.x
  146. Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med 2012;52:1658-1665. https://doi.org/10.1016/j.freeradbiomed.2012.02.008
  147. Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000;119:466-478. https://doi.org/10.1053/gast.2000.9365
  148. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002;122:1924-1940. https://doi.org/10.1053/gast.2002.33666
  149. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-1017. https://doi.org/10.1053/jhep.2003.50420
  150. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307. https://doi.org/10.1056/NEJMoa060326
  151. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135:100-110. https://doi.org/10.1053/j.gastro.2008.03.078
  152. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010;51:445-453. https://doi.org/10.1002/hep.23270
  153. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-1184. https://doi.org/10.1053/j.gastro.2008.06.047
  154. Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. J Hepatol 2011;55:1383-1390. https://doi.org/10.1016/j.jhep.2011.03.016
  155. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-851. https://doi.org/10.2337/dc07-2270
  156. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP, Jr, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-922. https://doi.org/10.2337/dc10-1068
  157. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-1188. https://doi.org/10.1001/jama.298.10.1180
  158. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298:2634-2643. https://doi.org/10.1001/jama.298.22.2634
  159. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003. https://doi.org/10.1038/79697
  160. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174. https://doi.org/10.1172/JCI13505
  161. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-894. https://doi.org/10.1016/S0140-6736(01)06042-1
  162. Uygun A, Kadayifci A, Isik A, Ozgurtas T, Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-544. https://doi.org/10.1111/j.1365-2036.2004.01888.x
  163. Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology 2011;54:1631-1639. https://doi.org/10.1002/hep.24558
  164. Haukeland JW, Konopski Z, Eggesbo HB, von Volkmann HL, Raschpichler G, Bjoro K, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009;44:853-860. https://doi.org/10.1080/00365520902845268
  165. Duseja A, Das A, Dhiman RK, Chawla YK, Thumburu KT, Bhadada S, et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 2007;6:222-226.
  166. Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008;28:200-208. https://doi.org/10.1111/j.1365-2036.2008.03723.x
  167. Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 2009;46:113-118. https://doi.org/10.1007/s00592-008-0067-2
  168. Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010;22:18-23. https://doi.org/10.1097/MEG.0b013e32832e2baf
  169. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904. https://doi.org/10.1007/s00125-011-2446-4
  170. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1333-1445. https://doi.org/10.1161/01.CIR.89.3.1333
  171. Nseir W, Mograbi J, Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci 2012;57:1773-1781. https://doi.org/10.1007/s10620-012-2118-3
  172. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-1292. https://doi.org/10.1053/j.gastro.2004.02.015
  173. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, Garcia- Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006;23:1643-1647. https://doi.org/10.1111/j.1365-2036.2006.02926.x
  174. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46:1453-1463. https://doi.org/10.1002/hep.21848
  175. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 2009;43:990-994. https://doi.org/10.1097/MCG.0b013e31819c392e
  176. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholinduced steatohepatitis: a pilot study. Hepatology 1996;23:1464- 1467. https://doi.org/10.1002/hep.510230624
  177. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;56:944-951. https://doi.org/10.1016/j.jhep.2011.08.018
  178. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008;14:6395-6400. https://doi.org/10.3748/wjg.14.6395
  179. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 2005;102:8132-8137. https://doi.org/10.1073/pnas.0500269102
  180. Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. Hepatol Res 2010;40:566-573. https://doi.org/10.1111/j.1872-034X.2010.00644.x
  181. Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011;46:101-107. https://doi.org/10.1007/s00535-010-0291-8
  182. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP 3rd, Larrick J, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofylline. Biochem Biophys Res Commun 1988;155:1230-1236. https://doi.org/10.1016/S0006-291X(88)81271-3
  183. Zein CO, Lopez R, Kirwan JP, Yerian LM, McCullough AJ, Hazen SL, et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism. Hepatology 2012;56:1291-1299. https://doi.org/10.1002/hep.25778
  184. Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:1946-1952. https://doi.org/10.1111/j.1572-0241.2004.40220.x
  185. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:2365-2368. https://doi.org/10.1111/j.1572-0241.2004.40064.x
  186. Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, et al. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008;2:196-201. https://doi.org/10.1007/s12072-008-9058-1
  187. Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011;10:277-286.
  188. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011;54:1610-1619. https://doi.org/10.1002/hep.24544
  189. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 2001;35:134-146. https://doi.org/10.1016/S0168-8278(01)00092-7
  190. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-778. https://doi.org/10.1002/hep.20092
  191. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rossle M, Cordes HJ, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebocontrolled trial. Hepatology 2010;52:472-479.
  192. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011;54:1011-1019. https://doi.org/10.1016/j.jhep.2010.08.030
  193. Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, Okamoto S, Okada M, et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006;12:322-326. https://doi.org/10.3748/wjg.v12.i2.322
  194. Ratziu V, Sheikh MY, Sanyal AJ, Lim JK, Conjeevaram H, Chalasani N, et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012;55:419-428. https://doi.org/10.1002/hep.24747
  195. Beraza N, Malato Y, Vander Borght S, Liedtke C, Wasmuth HE, Dreano M, et al. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut 2008;57:655-663. https://doi.org/10.1136/gut.2007.134288
  196. Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 2009;51:380-388. https://doi.org/10.1016/j.jhep.2009.03.025
  197. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010;51:1584-1592. https://doi.org/10.1002/hep.23569
  198. Lee JM, Lee YK, Mamrosh JL, Busby SA, Griffin PR, Pathak MC, et al. A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects. Nature 2011;474:506-510. https://doi.org/10.1038/nature10111
  199. Pillai AA, Rinella ME. Non-alcoholic fatty liver disease: is bariatric surgery the answer? Clin Liver Dis 2009;13:689-710. https://doi.org/10.1016/j.cld.2009.07.012
  200. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991;115:956-961. https://doi.org/10.7326/0003-4819-115-12-956
  201. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009;137:532-540. https://doi.org/10.1053/j.gastro.2009.04.052
  202. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008;6:1396-1402. https://doi.org/10.1016/j.cgh.2008.08.012
  203. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010:CD007340.
  204. Castillo J, Fabrega E, Escalante CF, Sanjuan JC, Herrera L, Hernanz F, et al. Liver transplantation in a case of steatohepatitis and subacute hepatic failure after biliopancreatic diversion for morbid obesity. Obes Surg 2001;11:640-642. https://doi.org/10.1381/09608920160557174
  205. Grimm IS, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am J Gastroenterol 1992;87:775-779.
  206. Brolin RE, Bradley LJ, Taliwal RV. Unsuspected cirrhosis discovered during elective obesity operations. Arch Surg 1998;133:84-88. https://doi.org/10.1001/archsurg.133.1.84
  207. Dallal RM, Mattar SG, Lord JL, Watson AR, Cottam DR, Eid GM, et al. Results of laparoscopic gastric bypass in patients with cirrhosis. Obes Surg 2004;14:47-53. https://doi.org/10.1381/096089204772787284
  208. Car Peterko A, Kirac I, Gaurina A, Diklic D, Bekavac-Beslin M. Diagnosis and management of acute and early complications of/after bariatric surgery. Dig Dis 2012;30:178-181. https://doi.org/10.1159/000336677
  209. Hammer HF. Medical complications of bariatric surgery: focus on malabsorption and dumping syndrome. Dig Dis 2012;30:182-186. https://doi.org/10.1159/000336681
  210. Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42:641-649. https://doi.org/10.1002/hep.20842
  211. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388-1393. https://doi.org/10.1542/peds.2006-1212
  212. Park JY, Ko JS, Seo JK, Lee R, Shin CH, Kang GH, et al. Nonalcoholic fatty liver disease progressing to cirrhosis in an obese boy with hypopituitarism. Korean J Pediatr Gastroenterol Nutr 2008;11:204-209.
  213. Moon JS, Lee KO, Hwang SS, Ko JS, Lee HK, Shin HJ, et al. Analytic Report on the Revised Korean National Sample Data from the National School Health Examination in 2009 and 2010. In: Korean Educational Development Institute ed. Korean Educational Development Institute MoH, Science and Technology. Seoul: Ministry of Health, Science and Technology (Korea), Korean Educational Development Institute, 2011.
  214. Park HS, Han JH, Choi KM, Kim SM. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am J Clin Nutr 2005;82:1046-1051. https://doi.org/10.1093/ajcn/82.5.1046
  215. Seo JW. Nonalcoholic fatty liver disease in children. Korean J Pediatr Gastroenterol Nutr 2011;14:209-221. https://doi.org/10.5223/kjpgn.2011.14.3.209
  216. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009;58:1538-1544. https://doi.org/10.1136/gut.2008.171280
  217. Steinberger J, Daniels SR, Eckel RH, Hayman L, Lustig RH, McCrindle B, et al. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2009;119:628-647. https://doi.org/10.1161/CIRCULATIONAHA.108.191394
  218. Roberts EA. Pediatric nonalcoholic fatty liver disease (NAFLD): a "growing" problem? J Hepatol 2007;46:1133-1142. https://doi.org/10.1016/j.jhep.2007.03.003
  219. Takahashi Y, Inui A, Fujisawa T, Takikawa H, Fukusato T. Histopathological characteristics of non-alcoholic fatty liver disease in children: Comparison with adult cases. Hepatol Res 2011;41:1066-1074. https://doi.org/10.1111/j.1872-034X.2011.00855.x
  220. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321. https://doi.org/10.1002/hep.20701
  221. Ko JS, Yoon JM, Yang HR, Myung JK, Kim H, Kang GH, et al. Clinical and histological features of nonalcoholic fatty liver disease in children. Dig Dis Sci 2009;54:2225-2230. https://doi.org/10.1007/s10620-009-0949-3
  222. Alkhouri N, De Vito R, Alisi A, Yerian L, Lopez R, Feldstein AE, et al. Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. J Hepatol 2012;57:1312-1318. https://doi.org/10.1016/j.jhep.2012.07.027
  223. Di Bonito P, Sanguigno E, Di Fraia T, Forziato C, Boccia G, Saitta F, et al. Association of elevated serum alanine aminotransferase with metabolic factors in obese children: sex-related analysis. Metabolism 2009;58:368-372. https://doi.org/10.1016/j.metabol.2008.10.010
  224. Yoo J, Lee S, Kim K, Yoo S, Sung E, Yim J. Relationship between insulin resistance and serum alanine aminotransferase as a surrogate of NAFLD (nonalcoholic fatty liver disease) in obese Korean children. Diabetes Res Clin Pract 2008;81:321-326. https://doi.org/10.1016/j.diabres.2008.05.006
  225. Riley MR, Bass NM, Rosenthal P, Merriman RB. Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists. J Pediatr 2005;147:839-842. https://doi.org/10.1016/j.jpeds.2005.07.020
  226. Patton HM, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 2008;135:1961-1971 e1962. https://doi.org/10.1053/j.gastro.2008.08.050
  227. Barlow SE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: Summary report. Pediatrics 2007;120:S164- S192. https://doi.org/10.1542/peds.2007-2329C
  228. Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006;44:458-465. https://doi.org/10.1002/hep.21262
  229. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009;50:1282-1293. https://doi.org/10.1002/hep.23119
  230. Ovchinsky N, Lavine JE. A critical appraisal of advances in pediatric nonalcoholic Fatty liver disease. Semin Liver Dis 2012;32:317-324.
  231. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008;48:119-128. https://doi.org/10.1002/hep.22336
  232. Bairati I, Meyer F, Jobin E, Gelinas M, Fortin A, Nabid A, et al. Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. Int J Cancer 2006;119:2221- 2224. https://doi.org/10.1002/ijc.22042

Cited by

  1. The Diagnosis of Nonalcoholic Fatty Liver Disease vol.86, pp.4, 2013, https://doi.org/10.3904/kjm.2014.86.4.405
  2. Nonalcoholic Fatty Liver Disease: Lifestyle Modification vol.86, pp.4, 2013, https://doi.org/10.3904/kjm.2014.86.4.416
  3. Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease vol.86, pp.4, 2013, https://doi.org/10.3904/kjm.2014.86.4.425
  4. Management of Non-alcoholic Fatty Liver Disease vol.15, pp.2, 2014, https://doi.org/10.4093/jkd.2014.15.2.93
  5. Comparison on the Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid in Patients with Abnormal Alanine Aminotransferase: Multicenter, Double-blinded, Randomized, Active-co vol.64, pp.1, 2013, https://doi.org/10.4166/kjg.2014.64.1.31
  6. Epigenetic Mechanisms Underlying the Link between Non-Alcoholic Fatty Liver Diseases and Nutrition vol.6, pp.8, 2013, https://doi.org/10.3390/nu6083303
  7. Clinical Correlation between Serum Cytokeratin-18 and Metabolic Parameters in Patients with Sonographic Non-alcoholic Fatty Liver Disease vol.64, pp.4, 2014, https://doi.org/10.4166/kjg.2014.64.4.206
  8. Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study vol.21, pp.4, 2013, https://doi.org/10.3350/cmh.2015.21.4.379
  9. The Influence of Metabolic Factors for Nonalcoholic Fatty Liver Disease in Women vol.2015, pp.None, 2015, https://doi.org/10.1155/2015/131528
  10. Visceral Adipose Tissue Area as an Independent Risk Factor for Elevated Liver Enzyme in Nonalcoholic Fatty Liver Disease vol.94, pp.9, 2013, https://doi.org/10.1097/md.0000000000000573
  11. Nonalcoholic Fatty Liver Disease as a Risk Factor of Arterial Stiffness Measured by the Cardioankle Vascular Index vol.94, pp.12, 2013, https://doi.org/10.1097/md.0000000000000654
  12. Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance vol.35, pp.3, 2013, https://doi.org/10.1111/liv.12552
  13. Hepatic fat, not visceral fat, is associated with gallbladder polyps: A study of 2643 healthy subjects vol.30, pp.4, 2013, https://doi.org/10.1111/jgh.12841
  14. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population vol.21, pp.20, 2013, https://doi.org/10.3748/wjg.v21.i20.6287
  15. Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease vol.94, pp.48, 2013, https://doi.org/10.1097/md.0000000000002159
  16. Discordance between conventional ultrasonography and ElastPQ for assessing hepatic fibrosis in chronic hepatitis B: frequency and independent factors vol.43, pp.2, 2013, https://doi.org/10.1007/s10396-015-0684-7
  17. Associations between White Blood Cell Count and the Development of Incidental Nonalcoholic Fatty Liver Disease vol.2016, pp.None, 2013, https://doi.org/10.1155/2016/7653689
  18. NONALCOHOLIC FATTY LIVER DISEASE BRAZILIAN SOCIETY OF HEPATOLOGY CONSENSUS vol.53, pp.2, 2016, https://doi.org/10.1590/s0004-28032016000200013
  19. The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease vol.22, pp.1, 2016, https://doi.org/10.3350/cmh.2016.22.1.146
  20. Clinical guidelines of non-alcoholic fatty liver disease: A systematic review vol.22, pp.36, 2016, https://doi.org/10.3748/wjg.v22.i36.8226
  21. Can Pharmacologic Therapy Induce Histologic Improvement in Non-alcoholic Steatohepatitis? vol.67, pp.5, 2013, https://doi.org/10.4166/kjg.2016.67.5.286
  22. Relationship between 25-Hydroxyvitamin D Levels and Liver Fibrosis as Assessed by Transient Elastography in Patients with Chronic Liver Disease vol.10, pp.5, 2013, https://doi.org/10.5009/gnl15331
  23. Nonalcoholic Fatty Liver Disease for Identification of Preclinical Carotid Atherosclerosis vol.95, pp.3, 2016, https://doi.org/10.1097/md.0000000000002578
  24. Association of nonalcoholic fatty liver disease with bone mineral density and serum osteocalcin levels in Korean men vol.28, pp.3, 2016, https://doi.org/10.1097/meg.0000000000000535
  25. Anti-inflammatory and antifatigue effect of Korean Red Ginseng in patients with nonalcoholic fatty liver disease vol.40, pp.3, 2013, https://doi.org/10.1016/j.jgr.2015.07.006
  26. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease vol.62, pp.8, 2013, https://doi.org/10.1007/s10620-017-4592-0
  27. Effects of Kamichunggantang on Lipoapoptosis and inflammation of NAFLD in db/db mice vol.17, pp.4, 2017, https://doi.org/10.1007/s13596-017-0276-8
  28. Effects of Kamichunggantang on Lipoapoptosis and inflammation of NAFLD in db/db mice vol.17, pp.4, 2017, https://doi.org/10.1007/s13596-017-0276-8
  29. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study vol.66, pp.2, 2013, https://doi.org/10.1136/gutjnl-2016-311854
  30. Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma vol.12, pp.3, 2017, https://doi.org/10.1371/journal.pone.0171922
  31. Epigenetics in non-alcoholic fatty liver disease vol.54, pp.None, 2013, https://doi.org/10.1016/j.mam.2016.11.008
  32. 대사증후군을 동반한 비알코올성 지방간염 치험 1례 vol.38, pp.2, 2013, https://doi.org/10.22246/jikm.2017.38.2.125
  33. Diagnosis of Non-Alcoholic Fatty Liver Disease Based on Clinical and Laboratory Data vol.18, pp.2, 2017, https://doi.org/10.4093/jkd.2017.18.2.102
  34. Radiologic Evaluation of Non-Alcoholic Fatty Liver Disease in Diabetic Patient vol.18, pp.2, 2017, https://doi.org/10.4093/jkd.2017.18.2.88
  35. Non-alcoholic Fatty Liver Disease: A Clinical Update vol.5, pp.3, 2017, https://doi.org/10.14218/jcth.2017.00013
  36. Genetic Polymorphisms of PNPLA3 and SAMM50 Are Associated with Nonalcoholic Fatty Liver Disease in a Korean Population vol.12, pp.3, 2013, https://doi.org/10.5009/gnl17306
  37. Management of Patients with Nonalcoholic Fatty Liver Disease with Lifestyle Modification vol.19, pp.2, 2013, https://doi.org/10.4093/jkd.2018.19.2.82
  38. Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease vol.19, pp.2, 2013, https://doi.org/10.4093/jkd.2018.19.2.88
  39. Association between cagA negative Helicobacter pylori status and nonalcoholic fatty liver disease among adults in the United States vol.13, pp.8, 2018, https://doi.org/10.1371/journal.pone.0202325
  40. Non-alcoholic fatty liver disease and cerebral small vessel disease in Korean cognitively normal individuals vol.9, pp.None, 2013, https://doi.org/10.1038/s41598-018-38357-x
  41. Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease vol.98, pp.6, 2013, https://doi.org/10.1097/md.0000000000014139
  42. Relationship between nonalcoholic fatty liver disease and bone mineral density in adolescents with obesity: a meta-analysis vol.12, pp.None, 2013, https://doi.org/10.2147/dmso.s192256
  43. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B vol.25, pp.1, 2013, https://doi.org/10.3350/cmh.2018.0040
  44. What are the main areas of focus to prevent or treat non‐alcoholic fatty liver disease? vol.20, pp.6, 2013, https://doi.org/10.1111/1751-2980.12751
  45. Association of low skeletal muscle mass with advanced liver fibrosis in patients with non‐alcoholic fatty liver disease vol.34, pp.9, 2013, https://doi.org/10.1111/jgh.14607
  46. Favorable impact of non‐alcoholic fatty liver disease on the cerebral white matter hyperintensity in a neurologically healthy population vol.26, pp.12, 2013, https://doi.org/10.1111/ene.14029
  47. A Pilot Study Assessing the Possible Combined Effect of Physical Activity and PNPLA3 rs738409 Polymorphism on the Risk for Non-Alcoholic Fatty Liver Disease in the Japanese Elderly General Populatio vol.13, pp.None, 2013, https://doi.org/10.2147/dmso.s217597
  48. Association between advanced fibrosis in fatty liver disease and overall mortality based on body fat distribution vol.35, pp.1, 2013, https://doi.org/10.1111/jgh.14778
  49. Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea vol.35, pp.1, 2013, https://doi.org/10.3904/kjim.2018.040
  50. Modelling NAFLD disease burden in four Asian regions—2019‐2030 vol.51, pp.8, 2013, https://doi.org/10.1111/apt.15673
  51. Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease? vol.26, pp.2, 2013, https://doi.org/10.3350/cmh.2020.0042
  52. Neddylation of sterol regulatory element-binding protein 1c is a potential therapeutic target for nonalcoholic fatty liver treatment vol.11, pp.4, 2020, https://doi.org/10.1038/s41419-020-2472-6
  53. Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk vol.115, pp.4, 2013, https://doi.org/10.14309/ajg.0000000000000572
  54. Non‐alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study vol.35, pp.5, 2013, https://doi.org/10.1111/jgh.14856
  55. Treatment of Non-Alcoholic Steatosis: Preclinical Study of a New Nutraceutical Multitarget Formulation vol.12, pp.6, 2013, https://doi.org/10.3390/nu12061819
  56. History of Nonalcoholic Fatty Liver Disease vol.21, pp.16, 2013, https://doi.org/10.3390/ijms21165888
  57. Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score vol.49, pp.5, 2013, https://doi.org/10.1093/ije/dyaa089
  58. Association of grip strength with non-alcoholic fatty liver disease: investigation of the roles of insulin resistance and inflammation as mediators vol.74, pp.10, 2020, https://doi.org/10.1038/s41430-020-0591-x
  59. NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea vol.39, pp.6, 2013, https://doi.org/10.1159/000514953
  60. Relationship between Muscle Mass and Non-Alcoholic Fatty Liver Disease vol.10, pp.2, 2021, https://doi.org/10.3390/biology10020122
  61. Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date vol.18, pp.4, 2013, https://doi.org/10.3390/ijerph18041616
  62. Impact of nonalcoholic fatty liver disease on the risk of metachronous colorectal neoplasia after polypectomy vol.36, pp.3, 2021, https://doi.org/10.3904/kjim.2019.360
  63. Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events vol.66, pp.8, 2021, https://doi.org/10.1007/s10620-020-06591-x
  64. Development and initial validation of the nonalcoholic fatty liver disease self‐management questionnaire vol.44, pp.5, 2021, https://doi.org/10.1002/nur.22164
  65. The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation‐wide Cohort Study vol.74, pp.6, 2013, https://doi.org/10.1002/hep.32034
  66. Genome‐wide association of individual vulnerability with alcohol‐associated liver disease: A Korean genome and epidemiology study vol.75, pp.2, 2013, https://doi.org/10.1002/hep.32115